Open Measurement Coordinating Network for Non-Pharmacological Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) Primary Prevention Trials (U24 Clinical Trail Not Allowed)
ID: 352326Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Open Measurement Coordinating Network for Non-Pharmacological Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) Primary Prevention Trials." This initiative aims to establish a national network that will develop, validate, standardize, and disseminate measurement methods for primary prevention trials focused on AD and ADRD, particularly addressing brain health equity among underserved populations. The network will serve as a centralized hub for innovative measurement approaches that encompass cognitive, behavioral, biological, and social factors impacting brain health. A total budget of $8 million is allocated for one award over a maximum period of five years, with applications due by June 15, 2024. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.

    Point(s) of Contact
    Files
    Title
    Posted
    The National Institute on Aging (NIA) under the Department of Health and Human Services has released a funding opportunity (RFA-AG-25-005) to establish an Open Measurement Coordinating Network for non-pharmacological Alzheimer’s Disease (AD) and AD-related Dementias (ADRD) primary prevention trials. This initiative aims to develop standardized measurement methods addressing cognitive, behavioral, biological, and social factors impacting brain health, particularly for underserved populations. The network will provide a centralized hub to validate and disseminate these measures, enhance equity in brain health approaches, and enable the development of future measurement projects. Key aspects of this funding opportunity include collaborative infrastructure, open-source methodologies, and a focus on sustainable practices. Applications are encouraged from diverse organizations, with a budget of $8 million committed for one award over a maximum period of five years. The application process involves substantial NIH involvement, and proposals must showcase comprehensive milestones, community engagement, and adherence to open science principles. The initiative reflects NIH’s strategic goals and seeks to mitigate cognitive decline through innovative, evidence-based approaches tailored to individuals' needs while advancing scientific collaboration and resource sharing.
    Similar Opportunities
    Alzheimer's Disease Research Centers (P30 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the establishment or renewal of Alzheimer's Disease Research Centers (ADRCs) through Grant Opportunity RFA-AG-24-001. This initiative aims to foster multidisciplinary collaboration and resource sharing among institutions dedicated to researching Alzheimer's Disease (AD) and related dementias (ADRD), with a focus on enhancing diverse perspectives in research. The program will provide a total of $32 million for seven awards in FY 2024, increasing to $65 million for 14 awards in both FY 2025 and FY 2026, with a maximum project budget of $2.925 million per year and a project period of up to five years. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov, with the application deadline set for September 26, 2025.
    Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel Therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD)." This initiative aims to streamline the early-stage evaluation of promising pharmacological interventions by bundling independent protocols for phase 1 clinical trials with phase 1b/phase 2a trials, focusing on non-amyloid/non-tau mechanisms that address cognitive and neuropsychiatric symptoms across various stages of the disease. The program is particularly significant given the rising prevalence of Alzheimer's and the associated economic burden, emphasizing the need for innovative treatments as the aging population grows. Eligible applicants include a diverse range of organizations, such as higher education institutions and community-based organizations, with proposals due by November 19, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-226.html.
    Notice of Intent to Publish a Funding Opportunity Announcement for Deriving Common Data Elements from Real-World Data for Alzheimer�s Disease (AD) and AD-Related Dementias (ADRD) (U24 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) aimed at developing Common Data Elements (CDEs) for Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) utilizing Real-World Data (RWD) from electronic health records and CMS claims. The objective is to enhance data harmonization and interoperability among disparate RWD systems, thereby facilitating more efficient research and faster production of real-world evidence. This funding opportunity, categorized as a cooperative agreement, has an estimated total program funding of $4 million, with a maximum award ceiling of $2.5 million, and is expected to result in one award. Interested applicants should prepare for the anticipated application due date in June 2024, following the expected publication of the NOFO in March 2024.
    Notice of Intent to Publish a Notice of Funding Opportunity for Centers on the Demography and Economics of Aging and Alzheimer�s Disease and Alzheimer�s Disease Related Dementias Coordinating Center (U24 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) intends to publish a Notice of Funding Opportunity (NOFO) for the establishment of a Coordinating Center focused on the Demography and Economics of Aging, including Alzheimer’s Disease and Alzheimer’s Disease-Related Dementias (AD/ADRD). The objective of this cooperative agreement is to create a hub that facilitates collaboration among various D&E Centers, scholars, and the research community, enhancing the scientific impact and fostering synergies across related programs and infrastructures. This initiative is crucial for promoting an inclusive research environment and raising awareness about the demography and economics of aging. The estimated total program funding is $1,320,000, with an award ceiling of $800,000, and the application process is expected to open in July 2024, with submissions due by October 2024. Interested applicants should prepare to develop meaningful collaborations in advance of the application deadline.
    New Approaches for Measuring Brain Changes Across Longer Timespans (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "New Approaches for Measuring Brain Changes Across Longer Timespans" (Funding Opportunity Number PAR-24-160). This initiative aims to encourage multidisciplinary research that innovatively measures brain activity, connectivity, and other aspects of neurodevelopment across various age groups, with a focus on longitudinal studies that can include both human and animal subjects. The opportunity is significant for advancing methodologies in brain research, particularly in understanding cognitive health and diseases over the lifespan. Interested applicants must submit their proposals by May 5, 2024, and include a Plan for Enhancing Diverse Perspectives (PEDP), adhering to rigorous methodological standards. For further information, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-160.html.
    Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Alzheimer's Drug-Development Program (Funding Opportunity Number: PAR-24-223), aimed at supporting the preclinical and early-stage clinical development of innovative drug candidates for Alzheimer's disease (AD). The program focuses on funding activities such as medicinal chemistry, pharmacokinetics, and Investigational New Drug (IND)-enabling studies, with the goal of advancing viable therapies to address the significant public health challenge posed by AD. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofits, and tribal organizations, with awards reaching up to $1.5 million over a period of up to five years for early-stage projects. Interested parties should submit their applications by November 5, 2027, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for research on neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) and related dementias (ADRD) through the R01 grant mechanism. This initiative aims to encourage studies that enhance understanding of the biobehavioral and neurobiological mechanisms associated with NPS, with the goal of identifying novel therapeutic targets for treatment and prevention. The research is critical for improving care and management strategies for patients and caregivers affected by these conditions, aligning with national efforts to combat Alzheimer's disease. Applications are accepted from a diverse range of eligible institutions, with key submission dates from January 5, 2025, to June 5, 2026. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-065.html.
    Notice of Intent to Publish a Notice of Funding Opportunity for Coordination Center for the Alzheimer�s Disease Sequencing Project Consortium (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Coordination Center for the Alzheimer’s Disease Sequencing Project Consortium, aimed at advancing research in Alzheimer's disease genetics. This initiative, which follows the approval of the concept by the National Advisory Council on Aging, will invite applications under an open competition framework, expanding eligibility for potential applicants. The funding opportunity is critical for fostering collaborations and innovative projects in the field of health, with an estimated total program funding of $1.6 million and a maximum award ceiling of $1 million for the selected applicant. The NOFO is expected to be published in November 2024, with applications due by February 14, 2025, and awards anticipated to be made by September 1, 2025.
    Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)" aimed at advancing exploratory research in Alzheimer's disease (AD) and related dementias (ADRD). This initiative invites applications for innovative methodologies, animal models, and techniques that require preliminary data, with a focus on addressing health disparities among under-resourced populations. The program emphasizes the importance of interdisciplinary research to combat the public health crisis posed by AD and ADRD, with a maximum funding amount of $275,000 available over two years. Interested applicants must submit their proposals by November 16, 2027, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Notice of Intent to Publish a Notice of Funding Opportunity for Early- and Late-Stage Clinical Trials for the Spectrum of Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Age-Related Cognitive Decline (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) intends to publish a Notice of Funding Opportunity (NOFO) for early- and late-stage clinical trials focused on Alzheimer's Disease, Alzheimer's Disease-Related Dementias, and age-related cognitive decline. This initiative aims to invite applications that propose innovative pharmacological and non-pharmacological interventions to address cognitive and behavioral changes associated with these conditions, as well as to enhance trial design and methodologies. The NOFO is expected to be published in December 2024, with application due dates in March, June, and October of 2025, and an estimated award date set for December 1, 2025. Interested applicants are encouraged to prepare collaborative projects in advance, as there are no cost-sharing requirements associated with this grant opportunity.